Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has been proposed as a potent tool to trigger apoptosis in cancer therapy. However, since $60% of tumour cell lines and most primary cancers are resistant to TRAIL-induced apoptosis, several combined therapy approaches aimed to sensitize cells to TRAIL have been developed. One of the major targets of these approaches are cFLIP proteins as they interfere with the initiation of apoptosis induction by TRAIL, are over-expressed in many cancers and their down-regulation enhances TRAIL sensitivity. Although, DNA-damaging agents such as 5-fluorouracil (5-FU), etoposide and adriamycin have been successfully employed due to their ability to trigger cFLIP L and cFLIP s down-regulation the molecular mechanisms underneath their action have been only partially elucidated. We have recently identified ataxia telangiectasia mutated (ATM) as a modulator of cFLIP L and cFLIP S protein levels in the DNA damage response. Here, we provide genetic evidence that ATM kinase activity is required to trigger 5-FU-and neocarzinostatin-dependent cFLIP L and cFLIP S downregulation, which in turn sensitize hepatocellular carcinoma (HCC) cell lines to TRAIL. ATM activity triggers cFLIP proteins down-regulation in HCC cells independently on p53 and enhances cFLIP L ubiquitination in response to DNA damage. Therefore, we propose that ATM kinase mediates the interplay between DNA damage and death receptor signalling and suggest that expression of catalytically competent ATM in tumour cells may play a key role for successful combinatorial use of TRAIL receptor agonists and DNA-damaging drugs in cancer therapy.
Introduction
Since the discovery of its tumour-specific killing potential, the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has been extensively studied as a potential novel drug for use in cancer therapy. The observation that systemic administration of TRAIL in mice was not associated with deleterious side effects, described for other apoptosis-inducing members of the tumour necrosis factor cytokine family, suggested TRAIL as a promising candidate for cancer therapy (1) (2) (3) (4) . However, as several cancer cell lines and most primary cancers are resistant to TRAIL-induced apoptosis, an important challenge is to understand the molecular mechanism for TRAIL resistance and to identify novel therapeutic strategies to sensitize tumour, but not normal, cells to TRAIL-induced apoptosis.
TRAIL can interact with five different receptors (reviewed in ref. 5 ). TRAIL triggers apoptosis via two of its receptors, TRAIL-R1 (DR4) and TRAIL-R2 (DR5). Upon binding of TRAIL or agonistic antibodies to TRAIL-R1 or TRAIL-R2, the death-inducing signalling complex (DISC) is formed. DISC formation ensues by recruitment of the adaptor protein Fas-associated death domain and the two initiator caspases, caspase-8 (FLICE/MACH) and caspase-10. When recruited to the DISC, these proteases form dimers. This step is crucial for their activation. DISC-activated caspases 8 and 10 cleave effector caspases which following an additional auto-catalytic step are fully activated and execute the apoptotic response (reviewed in ref. 5 ). The best-characterized modulators of the activation of the initiator caspases 8 and 10 are the cellular FLICE-inhibitory proteins, cFLIP, which are structurally very similar to these two caspases. However, cFLIP proteins are catalytically inactive. They compete with caspases 8 and 10 for DISC association and can form heteromeric complexes with these caspases, thereby interfering with their proper activation with the consequence of inhibiting apoptosis. As cFLIP proteins interfere with the initial proteolytic step of apoptosis induction by TRAIL, they are very potent suppressors of this cell death pathway. Different isoforms of cFLIP, arising from alternative splicing, are normally present in most cell types (reviewed in ref. 6 ). The short isoform of cFLIP (cFLIP S ) behaves as a pure inhibitor of procaspase-8 activation and Fas-induced apoptosis, as it contains only the DED domains required for the DISC recruitment. The long isoform of cFLIP (cFLIP L ) is the most abundant isoform in many cancer cell lines. Like caspases 8 and 10, cFLIP L has two DED domains and the p18 and p10 subunits. However, unlike the two caspases, cFLIP L lacks the cysteine residue in the active site and it is therefore catalytically inactive. Nevertheless, in some contexts, cFLIP L has been reported to exert functions other than apoptosis inhibition and, in some contexts, it may act as a potent co-activator of procaspase-8 (reviewed in ref. 6 ).
Importantly, aberrant up-regulation of cFLIP proteins has been shown to be present in a number of cancer and its small interfering RNA-mediated down-regulation was often found to be sufficient to sensitize TRAIL-resistant tumour cell lines to apoptosis induction by TRAIL (7, 8) . Consequently, the identification of drugs which would sensitize cancer cells to TRAIL by cFLIP down-regulation ensued, resulting in the identification of DNA-damaging drugs as potent down-regulators of cFLIP and sensitizers to TRAIL-induced apoptosis (reviewed in ref. 4) . As an example, the DNA-damaging agent 5-fluorouracil (5-FU), a pyrimidine analogue widely used as a chemotherapeutic drug in cancer therapy, triggers down-regulation of cFLIP, an event that has been shown to be sufficient to sensitize cancer cells to TRAIL-induced apoptosis (9) . Since this effect was tumour cell specific (10), the combination of TRAIL receptor agonists with DNA-damaging drugs was proposed as a novel strategy for the treatment of several types of cancer (reviewed in refs [11] [12] [13] .
We recently showed that the radiomimetic drug Neocarzinostatin (NCS) may trigger the down-regulation of cFLIP proteins by inducing the activation of the ataxia telangiectasia mutated (ATM) kinase in response to DNA damage. ATM kinase activity negatively modulates stability of cFLIP at the protein level, thereby promoting the sensitivity to apoptosis induction by Fas (CD95/APO-1), a TRAIL-R1/R2-related death receptor (14) .
Here, we present evidence that DNA damage-induced activation of ATM causes down-regulation of both cFLIP L and cFLIP S and sensitization to TRAIL-induced apoptosis. Importantly, genetic inactivation of ATM but not of p53 impairs TRAIL sensitization by DNA-damaging agents such as NCS and 5-FU. Proteasome inhibition leads to cFLIP L accumulation only in ATM-proficient cells, whereas cFLIP S levels increase in the presence of proteasome inhibitors independently on ATM kinase activity. Moreover, DNA damage-induced activation of ATM selectively renders cFLIP L more susceptible to ubiquitination and degradation via the ubiquitin-proteasome pathway. Thus, we show that ATM activity triggers the down-regulation of cFLIP L and cFLIP S by DNAdamaging agents through different mechanisms, and therefore contributes to DNA damage-induced sensitization to TRAILinduced apoptosis.
Materials and methods

DNA constructs
pcDNA3-Flag-ATM-wt and pcDNA3-Flag-ATM-kin -were kindly provided by M.Kastan. shATM construct and its control were kindly provided by Y.Lerenthal and Y.Shiloh (15) . shp53 construct and its control were kindly provided by S.Soddu (16) . More in detail, the following constructs were used: shATM (ATM#1, position 912), 5#-gatccccGACTTTGGCTGTCAACTTTCGttcaagagaCGAAAGTTGACAGCCAAAGTCtttttggaaa-3#; shcontrol, 5#-gatccccGGGATATCCCTCTAGATTAttcaagagaTAATCTAGAGGGATATCCCtttttggaaa-3#; shp53, 5#-gatccccGACTCCAGTGGTAATCTACttcaagagaGTAGATTACCACTGGAGTCtttttggaaa-3# and shp53scramble (shscramble), 5#-gatccccCTATAACGGCGCTCGATATttcaagagaATATCGAGCGCCGTTATAGtttttggaaa-3#.
Antibodies and other reagents
The following antibodies and reagents were used: anti-phospho-Ser1981-ATM (Cell Signaling Technology, Beverly, MA), anti-ATM (2C1; Santa Cruz Biotechnology, Santa Cruz, CA), anti-FLIP (S and L) (H-202 rabbit polyclonal; Santa Cruz Biotechnology), anti-FLIP (S and L) (NF6; Alexis Biochemicals, Farmingdale, NY), anti-b-tubulin (Sigma, St Louis, MO), anti-p53 (Pab240; Santa Cruz Biotechnology), anti-ubiquitin (FK-2; Upstate, Billerica, MA). iz-TRAIL (human isoleucine zipper) has been kindly provided by H.Walczak (10), NCS, 5-FU and MG132 were commercially available (Sigma) as well as KU-55933 (Calbiochem, Merck, Darmstadt, Germany), whereas pifithrin-a was kindly provided by F.Maina.
Cell culture and transfections C3ABR and L6 cells (kindly provided by M.Lavin and Y.Shiloh), GM-03189 and GM-02782 (kindly provided by E.Cundari) cell lines, L6pCDNA, L6-Flag-ATM-wt and L6-Flag-ATM-Kin -, were cultured as described previously (14) . The human hepatocellular carcinoma (HCC) cell line HepG2-TR was maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum according to Ganten et al. (9) . The temperature-sensitive ts20 Balb/ C 3T3 clone A31 fibroblast cell line and its E1-corrected H38.5 derivative were cultured as described previously (17) .
A31 fibroblast cell line and its E1-corrected H38.5 derivative were transfected by Lipofectamine 2000 according to the manufacturer's instruction (Invitrogen, Carlsbad, CA). HCC cell lines were stably transfected with psuper-shControl, psuper-shATM, psuper-shp53Srcamble and psuper-shp53 with Lipofectamine 2000 and positive clones were selected in the presence of puromycin (2 lg/ml). HEK-293T cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and transfected with the calcium phosphate precipitation method as described previously (18) .
Analysis of apoptosis C3ABR, GM-03189, GM-02782, L6, L6pCDNA and L6-Flag-ATM-wt cells lines were treated to undergo apoptosis with 500 ng/ml of iz-TRAIL (human isoleucine zipper). HepG2-TR HCC cells were treated to undergo apoptosis with 10 ng/ml of iz-TRAIL. Where indicated cells were also treated with NCS (500 ng/ml) or 5-FU (100 lg/ml), for 3 and 6 h, or stimulated in the presence of 5 lM pifithrin p53 inhibitor, which was added 30 min before stimulation with TRAIL. Apoptosis was quantified by propidium iodide (Sigma) using a FACScanto (Becton Dickinson, Lincoln Park, NJ).
Specific apoptosis was determined as follows: (% of apoptotic cells with TRAIL À % of apoptotic cells without TRAIL)/(100 À % of apoptotic cells without TRAIL).
Immunoblotting and immunoprecipitation
Cell extracts were prepared as described previously (14) . For immunoblotting, 80-100 lg protein extract were separated by sodium dodecyl sulphatepolyacrylamide gel electrophoresis, blotted onto nitrocellulose membrane and detected with specific antibodies. All immunoblots were revealed by enhanced chemiluminescence (ECL) (Amersham, Arlington Heights, IL).
Statistical methods
All data were analysed and presented as mean ± SD (n , 10). The significance of differences between populations of data was assessed as described previously (14) .
Results ATM kinase activity is required for DNA damage-dependent downregulation of cFLIP protein levels and for the enhancement of TRAIL sensitivity To evaluate whether ATM activity may modulate TRAIL sensitivity, similarly to Fas (14) , lymphoblastoid cell lines proficient (C3ABR) or deficient (L6, GM-02782 and GM-03189) for ATM kinase activity were incubated for 24 h in the presence of iz-TRAIL to strongly induce TRAIL-dependent apoptosis. All the ATM-deficient cell lines showed resistance to TRAIL-induced apoptosis, suggesting that ATM kinase activity may modulate sensitivity of cells to TRAIL ( Figure 1A ). We therefore tested the hypothesis that ATM kinase activity may mediate DNA damage-dependent sensitization to TRAIL-induced apoptosis via down-regulation of cFLIP. ATM-proficient and -deficient lymphoblastoid cell lines, previously established in our laboratory (14) , starting from A-T L6 cells were incubated in the presence of NCS. This treatment strongly down-regulated cFLIP in ATM-proficient L6-ATM-wt but not ATM-deficient L6-pCDNA3 cells (14) . Consistent with our hypothesis, NCS pretreatment significantly sensitized ATM-expressing cells but not ATM-deficient cells to TRAIL-induced apoptosis, already at short time of exposure when TRAIL stimulation per se failed to significantly trigger cell death ( Figure 1B ; supplementary Figure S1A is available at Carcinogenesis Online). This result indicated that ATM is required both for TRAIL sensitivity as well as for DNA damageinduced TRAIL sensitization. We next found that, similarly to NCS, 5-FU treatment induced down-regulation of both cFLIP L and cFLIP S isoforms, as well as TRAIL sensitivity only in ATM-competent cells ( Figure 1C and D) . Furthermore, we could show that 5-FU failed to down-regulate cFLIP in cells reconstituted with a kinase-defective ATM (L6-ATM-Kin -) (supplementary Figure S1B is available at Carcinogenesis Online). Consistently, these cells are resistant to 5-FUdependent sensitization to TRAIL induced apoptosis (supplementary Figure S1C is available at Carcinogenesis Online), confirming that ATM kinase activity is required for cFLIP down-regulation and sensitization to apoptosis induction by TRAIL.
ATM kinase activity is required for 5-FU and NCS ability to sensitize HCC cells to TRAIL-induced apoptosis We next tested whether DNA damage-induced ATM activation could be required to modulate cFLIP levels and TRAIL sensitivity in HCC cells as a model system for epithelial cancer in which the potential of DNA-damaging agents as sensitizers to TRAIL-induced apoptosis is well established. Using the HepG2-TR model system (a cell line derived from HepG2 cells by continuous culture in the presence of TRAIL for several months, a treatment which rendered the surviving cells TRAIL resistant), it was shown previously that 5-FU pretreatment results in a down-regulation of both cFLIP L and cFLIP S isoforms and that this is important for sensitization of TRAIL-resistant HCC cells to TRAIL (9) . However, the molecular mechanism through which 5-FU modulated cFLIP levels remained inscrutable. We confirmed that 5-FU in HepG2-TR cells triggered down-regulation of cFLIP L and cFLIP S , and more interestingly induced ATM kinase activation (Figure 2A) , similarly to what observed in lymphoblastoid cells. Importantly, small interfering RNA-mediated down-regulation of ATM ablated DNA damage-induced down-regulation of cFLIP L and cFLIP S, (Figure 2A ) as well as TRAIL sensitization ( Figure 2B ) in HepG2-TR cells. Similarly, ATM kinase activity was necessary to trigger cFLIP down-regulation and TRAIL sensitization also in response to NCS treatment ( Figure 2C and D) . Overall, these data demonstrate that ATM is required also in the HCC cell line HepG2-TR to downmodulate cFLIP L and cFLIP S isoforms and to sensitize them to TRAIL in response to different DNA-damaging agents.
5-FU and NCS trigger cFLIP down-regulation and sensitize hepatocellular carcinoma cells to TRAIL independently on p53 p53 was previously reported to modulate cFLIP protein levels and to play a role in TRAIL-induced apoptosis (19, 20) . However, other ATM links DNA damage to death receptors reports suggested that these effects were independent on p53 (9). Since p53 is a well-known substrate of ATM following DNA damage (21, 22) , we therefore next addressed the question whether ATM kinase activity may modulate cFLIP protein expression through p53. To answer this question, we impaired p53 function in p53-proficient HepG2-TR cells, both genetically, by small interfering RNA, and pharmacologically with pifithrin-a, a known p53 inhibitor. Consistent with previous reports (9), 5-FU-as well as NCS-triggered downregulation of cFLIP proteins and enhanced TRAIL sensitivity were independent on p53 expression ( Figure 3A-D) . Together, these results indicate that in HCC cells, the kinase activity of ATM modulates the level of cFLIP expression and TRAIL apoptosis sensitivity largely independently of p53.
ATM kinase activity selectively modulates cFLIP L protein stability through the proteasome pathway We then sought to investigate the molecular mechanism by which ATM kinase activity upon DNA damage may trigger cFLIP downregulation. We have shown previously that ATM kinase activation in response to NCS treatment impinges on cFLIP protein stability (14) . Furthermore, using the ATM-proficient lymphoblastoid cell line, C3ABR, treated with NCS to trigger DNA damage and ATM activation, we could show that NCS treatment does not down-regulate cFLIP messenger RNA levels (supplementary Figure S2 is available at Carcinogenesis Online; data not shown). To test whether ATM may modulate cFLIP degradation through the proteasome pathway, we incubated ATM -proficient and -deficient cell lines in the presence or in the absence of the proteasome inhibitor MG132. As already shown (14) , we confirmed that the basal activity of ATM kinase negatively modulates cFLIP protein levels, which are enhanced in ATM-deficient cells or catalytically inactive cells ( Figure 4A ). More importantly, MG132 treatment significantly increased cFLIP S protein levels independently on ATM, whereas it induced cFLIP L protein levels compared with untreated cells only in those cells competent for ATM kinase activity, suggesting that ATM functionality is required for the down-regulation of cFLIP L protein stability by the proteasomal pathway ( Figure 4A) . Consistently, ATM kinase activity is required also in C3ABR cells for the modulation of cFLIP protein levels and proteasome inhibition impaired ATM's ability to trigger cFLIP down-regulation in response to DNA damage ( Figure 4B ). Importantly, also in this cellular system, NCS-triggered decrease in cFLIP results in sensitization to TRAIL that was prevented by ATM kinase activity inhibition, in the presence of the specific inhibitor KU-55933 (23) (Figure 4C and D) .
To strengthen our observation on the ability of ATM activity and of the proteasome signalling in the modulation on cFLIP proteins triggered by DNA damage, we treated HepG2-TR cells with NCS in the presence or in the absence of the proteasomal inhibitor MG132. We could show that, similarly to C3ABR cells, cFLIP L as well as cFLIP S decrease in response to DNA damage and ATM activation, required protesomal activity as it was fully blocked by MG132 pre-incubation. 
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Furthermore, using a genetic approach, we could show that, according to our hypothesis that cFLIP down-regulation is largely independent on p53, as p53 down-regulation through specific shp53 interference, does not prevent cFLIP L and cFLIP S degradation by the proteasome pathway in response to NCS ( Figure 4E ). These data, along with the results obtained in the lymphoblastoid cell lines ( Figure 4A ) suggest that ATM kinase activity modulates cFLIP L and cFLIP S protein levels through different mechanisms and selectively triggers cFLIP L degradation through the proteasome pathway.
To verify whether ATM kinase activation may trigger cFLIP L degradation through the ubiquitin pathway, we took advantage of a temperature-sensitive cell line deficient for the E1 ubiquitin-activating enzyme activity upon shift from the permissive (32°C) to the nonpermissive (39°C) temperature, named A31N-ts20 (17) . As a positive control, we used the H38.5 cell line derived from the ts-20, upon cell transfection with a construct for the expression of a wild-type E1 that rescued the ts phenotype (17) . Both cell lines were transiently transfected with a construct that drives the expression of cFLIP L , shifted or not to the non-permissive temperature and incubated with NCS to trigger DNA damage and ATM kinase activation. As expected, at the permissive temperature NCS treatment triggered cFLIP L downregulation in both cell lines (data not shown). Conversely, at the nonpermissive temperature, the lack of functional E1 (A31N-ts20 cells) prevented cFLIP L degradation in response to NCS treatment, whereas E1 reconstitution (H38.5 cells) rescued cFLIP L protein levels downregulation ( Figure 5A ; supplementary Figure S3A is available at Carcinogenesis Online). To investigate the ability of ATM kinase to modulate cFLIP L protein ubiquitination, we co-transfected HEK293T cells with cFLIP isoforms along with Ubiquitin-HA, in the presence or in the absence of ATM. Cells were incubated in the presence of MG132 to trigger the accumulation of ubiquitinated proteins and the ubiquitination of immunoprecipitated cFLIP proteins analysed by immunoblotting. We could show that ATM over-expression significantly enhances cFLIP L ubiquitination ( Figure 5B ). Interestingly, ATM failed to trigger cFLIP S ubiquitination, consistent with the results obtained by blocking the proteasome (Figure 4A ), enforcing the idea that ATM modulates cFLIP L and cFLIP S through different mechanisms.
To further support the hypothesis that ATM activity is required for cFLIP L regulation through the ubiquitin-proteasome pathway, endogenous cFLIP was immunoprecipitated from the ATM-proficient cells, C3ABR, or ATM-deficient cells, L6-pCDNA3, incubated with NCS to trigger DNA damage and ATM activation, along with MG132 to prevent the degradation of ubiquitinated proteins. Immunoblotting with anti-ubiquitin and with anti-FLIP antibodies revealed that DNA damage significantly enhances cFLIP L protein ubiquitination only in the presence of ATM kinase (supplementary Figure S3 is available at Carcinogenesis Online). Moreover, incubation with the ATM kinase inhibitor KU-55933 reduced as expected ATM kinase activation in response to DNA damage and more interestingly, significantly impaired the enhancement of cFLIP L ubiquitination triggered by NCS treatment in ATM-proficient cells ( Figure 5C ), allowing the conclusion that ATM kinase activity is required for the DNA damage-dependent ubiquitination and degradation of cFLIP L .
Discussion
The main requirements for an anticancer therapy are high antitumour efficacy and low toxicity for normal cells. The observation that TRAIL selectively kills tumour cells supports TRAIL as one of the most promising novel agents for cancer therapy (1-4) . However, many tumourigenic cell lines are resistant to TRAIL-induced apoptosis, underscoring the requirement for the identification of those molecular pathways that may be exploited to selectively sensitize resistant cancer cells to TRAIL. Some well-known chemotherapy approaches have been proposed in combination with TRAIL, among them, DNA-damaging agents, such as 5-FU, cisplatinum, etoposide and adriamycin (9), HDAC inhibitors (24, 25) and proteasome inhibitors such as bortezomib (26) (27) (28) . Although these co-treatments significantly sensitize tumourigenic cells to TRAIL and in most cases do not increase the toxicity for normal cells (10) , the molecular mechanisms underlining their effect are still largely obscure. One of the main features of TRAIL resistance, is the aberrantly high level of cFLIP proteins expression, as described in HCC and in many other tumours (7) (8) (9) 19, 20) . Interestingly, cFLIP down-regulation has been provided as a valuable tool to enhance TRAIL sensitivity and more importantly, several chemotherapeutic agents among which DNA-damaging ATM links DNA damage to death receptors agents such as 5-FU, proteasome inhibitors, such as bortezomib and HDAC inhibitors, have been reported to impinge on TRAIL sensitivity through their ability to down-regulate cFLIP proteins expression, although the signalling pathways by which they exert this function are still largely obscure (9, (24) (25) (26) (27) (28) (29) . We have recently identified a novel molecular mechanism through which DNA double-strand breaks down-regulate cFLIP protein levels and enhance Fas sensitivity. Double-strand breaks trigger ATM kinase activation, which in turn is responsible, through a yet undiscovered mechanism, for cFLIP down-regulation as its genetic or pharmacological inhibition results in Fas resistance, whereas its induction may enhance Fas sensitivity (14) .
Here, we provide evidence that ATM kinase activity is required by DNA-damaging chemotherapy drugs to trigger cFLIP proteins downregulation and to therefore enhance TRAIL sensitivity in a tumourigenic context. Importantly, using a genetic approach, we could demonstrate that DNA-damaging agents, such as NCS and 5-FU, require ATM kinase activity to modulate cFLIP levels and to therefore exert their function as enhancer of TRAIL sensitivity (Figure 1 ). To further support our hypothesis, we moved to the HCC system where it is well established that 5-FU enhances TRAIL sensitivity through cFLIP protein down-regulation, although the underneath molecular mechanism has not been elucidated so far (9) . We could show that indeed 5-FU requires ATM kinase activity to mediate cFLIP protein down-regulation. Genetic ablation of functional ATM results in the loss of 5-FU-dependent TRAIL sensitivity also in this system (Figure 2) , allowing the conclusion that 5-FU requires ATM kinase activity to enhance TRAIL sensitivity of TRAIL-resistant cancer cells. According to our finding, the functionality of ATM could be demanded for the success of combined therapy with TRAIL and DNA-damaging agents and its impairment may account for the failure of such approach in some tumorigenic contexts. Conversely, it has been shown that in melanoma cancer cell lines, the inhibition of ATM activity may sensitize cells to TRAIL, suggesting that ATM may differently modulate TRAIL sensitivity, most probably depending on the specific cellular context (30) .
We then investigated more deeply the molecular mechanism through which ATM kinase activity may modulate cFLIP protein levels. One central issue regards the role of p53 in the modulation of cFLIP levels and death receptor-induced apoptosis. Since p53 is mutated or lost in most of the tumours and ATM is a well-known modulator of p53 activity in response to DNA damage (21, 22) , we asked whether ATM-dependent cFLIP down-regulation required p53. Interestingly, p53 may modulate in some tumorigenic contexts but not in others, death receptor-induced apoptosis through several mechanisms including the direct transcriptional regulation of death receptors, as well as transcriptional and post-translational modulation of cFLIP (reviewed in ref. 4) . Consistent with previous reports (9), we could show that 5-FU could be widely used to sensitize HCC cells to TRAIL, regardless of p53 status (Figure 3 ). More interestingly, in HCC cells, 5-FU-dependent cFLIP protein down-regulation is largely independent on p53 (Figure 3) , differently from what described in ovarian carcinoma cell lines treated with cisplatin (31) . We can speculate that these apparent discrepancies may be mainly due to the specific different cellular contexts and to the different mechanism of action of the drugs involved in these studies. Indeed, depending ATM links DNA damage to death receptors on the cellular context and on the specific chemotherapeutic drug, other cellular components beside ATM may be differently targeted and therefore may contribute to modulate cFLIP protein levels through multiple, only partially overlapping pathways. Consistent with this hypothesis, it has been recently shown that radiation and anticancer drugs can down-regulate cFLIP L and cFLIP S through different mechanisms in different cellular systems (32) . Furthermore, the two isoforms may differently contribute to chemoresistance depending on the cellular context (20, 33, 34) .
Here, we could show that upon NCS treatment, ATM promotes cFLIP L protein degradation through the ubiquitin-proteasome system (Figures 4-6) . Several reports show that the treatment with the proteasome inhibitor bortezomib for 12-24 h triggers cFLIP downregulation and therefore enhances TRAIL sensitivity (24, (26) (27) (28) . We performed a time course analysis of the effect of bortezomib and MG132 treatments on cFLIP protein levels. Interestingly, we could observe that while short-time incubations (1-3 h) result in cFLIP protein up-regulation, longer exposures (12-24 h) trigger cFLIP protein levels decrease (data not shown), as described previously (24, (26) (27) (28) , suggesting that while short-time treatments directly affect only cFLIP protein stability, longer inhibition of the proteasome results most probably in a more complex modulation of cFLIP protein expression also through transcriptional pathways (29) . Interestingly, although we provided evidence for the down-regulation of cFLIP S protein levels by ATM kinase (Figures 1-3) as well as by the proteasome machinery (Figure 4 ), we could show that ATM activity does not impinge on cFLIP S ubiquitination-and proteasome-dependent degradation (Figures 4-6) . Recently, cFLIP S translation has been shown to be down-regulated by DNA-damaging agents (34) . Future experiments will clarify the molecular mechanism through which ATM modulates cFLIP S protein levels.
It has been recently shown that ubiquitin-proteasome pathway is induced in response to ATM kinase activation. NCS treatment endogenously increases ubiquitin conjugates in lymphoblastoid cells. A-T cells show an attenuated ability to mount the ubiquitination response to stress, supporting a role for ATM in the modulation of the ubiquitination machinery (35) . This role of ATM would be in agreement with the identification, through large-scale proteomic approaches, of several components of the proteasome-ubiquitin machinery among putative ATM substrates (36, 37) . Interestingly, ATM kinase has been shown to be able to modulate protein ubiquitination by direct phosphorylation of the target, which in turn modulates its interaction with the proteasome-ubiquitin machinery, or by phosphorylation of the E3 ubiquitin ligase that directly triggers target ubiquitination (38) (39) (40) .
Recently, the activity of JNK kinase as well as of ITCH E3 ubiquitin ligase have been involved in the down-regulation of cFLIP L in response to some DNA-damaging agents in specific cellular contexts (31, 32) . Furthermore, JNK promotes cFLIP L degradation downstream tumour necrosis factor through the phosphorylation of ITCH ubiquitin ligase (41) . Future experiments will clarify whether ATM may impinge on cFLIP L protein stability through this signalling pathway or through an alternative mechanism.
To summarize, our studies identify ATM as a molecular linker between the DNA damage-induced apoptosis and death receptorinduced cell death. ATM kinase activation in response to DNA damage may trigger a cascade of events that impinges also on death receptor-induced apoptosis ( Figure 6 ). Interestingly, BID, a well known amplifier of death receptor-induced cell death, has been recently identified as a novel ATM kinase substrate (42, 43) , although the effect of this phosphorylation on death receptor-induced apoptosis has not been clarified yet.
We therefore point to ATM kinase activity as a key player for the exploit of DNA-damaging chemotherapy drugs to trigger TRAIL sensitization and to set up combined therapies.
Supplementary material
Supplementary Figures S1-S3 can be found at http://carcin.oxford journals.org/ 6 . ATM kinase activity modulates FLIP protein levels therefore connecting DNA damage signalling to death receptor-induced apoptosis. Death receptor stimulation triggers caspase-8 and -10 activation and the subsequent apoptotic cascade. cFLIP proteins impair caspase-8 and -10 activation preventing cell death. DNA-damaging agents trigger ATM activation, which promotes cFLIP L protein degradation via the ubiquitinproteasome pathway and cFLIP S down-regulation through a jet unknown mechanism, therefore sensitize cells to death receptor-induced apoptosis.
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